Metabolic
Series

Retatrutide — 10 mg

Retatrutide is an investigational triple hormone receptor agonist that activates receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This novel research compound represents a new class of multi-receptor agonists being studied for metabolic applications.

• A Phase 2 clinical trial published in the New England Journal of Medicine (Jastreboff et al., 2023) examined retatrutide in adults with obesity over 48 weeks. Researchers observed dose-dependent changes in body weight and metabolic parameters across treatment groups.
• A meta-analysis published in PMC (2024) analyzing three randomized controlled trials encompassing 878 patients reported that retatrutide demonstrated statistically significant effects on body weight, BMI, waist circumference, fasting plasma glucose, and HbA1c compared to placebo.
• Research published in Nature Medicine (2024) examined retatrutide's effects on hepatic fat content in subjects with metabolic dysfunction-associated steatotic liver disease, documenting substantial changes in liver fat measurements at 24 weeks.
• Phase 3 TRIUMPH-4 trial results (December 2025) demonstrated significant improvements in both weight and pain scores in subjects with knee osteoarthritis over 68 weeks of treatment.

Triple agonist targeting GIP, GLP-1, and glucagon receptors. Research suggests these pathways are involved in glucose homeostasis, appetite regulation, energy expenditure, and lipid metabolism.

• Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526.PMID: 37366315
• Efficacy and safety of retatrutide for obesity treatment: systematic review and meta-analysis.PMID: PMC12026077
• Nature Medicine. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. 2024. doi:10.1038/s41591-024-03018-2